Wnt10B, Recombinant, Human (Protein Wnt-10b, Protein Wnt-12, Wnt12)

Wnt-10b is a 42-44kD member of the Wnt family of secreted, highly conserved, cysteine-rich glycoproteins that play important roles in vertebrate pattern formation, cell fate decision, axon guidance, and tumor formation. Human Wnt-10b cDNA encodes a 389aa precursor that contains a 28aa signal sequence plus a 361aa mature protein that contains two glycosylation sites, three potential phosphorylation sites, and a potential palmitoylation site. Human Wnt-10b shares 97-99% aa identity with mouse, rat, equine, porcine, and canine Wnt-10b. Wnt-10b plays a critical role in maintaining mesenchymal stem cells and determining whether they differentiate to adipocytes or osteoblasts. Mouse Wnt-10b deletion produces age-dependent loss of bone mass due to defective production of osteoblasts, while transgenic over-expression increases postnatal osteoblast differentiation and inhibits adipocyte differentiation. Ectopic expression of Wnt-10b in an obesity and diabetes-prone background, such as the ob/ob mouse, inhibits obesity. In mouse skeletal muscle, Wnt-10b is expressed inversely with SREBP1c and increases insulin sensitivity. In humans, a missense polymorphism is responsible for a malformation of hands and feet, while a C256Y inactivating mutation is associated with severe early-onset obesity. Wnt-10b is mainly produced by stem cells and pre-osteoblasts, but also by adult bone marrow CD8+ T lymphocytes stimulated with parathyroid. In some hepatocellular carcinomas, Wnt-10b can inhibit cancer cell growth, but in others, it can act synergistically with FGFs to stimulate cell growth. Several Wnts, including Wnt-10b, are expressed in both normal and/or malignant colon tissues.\n\nSource:\nRecombinant corresponding to aa1-389 human Wnt-10b expressed in Chinese Hamster Ovary cell line, CHO.\n\nMolecular Weight:\n~40kD\n\nBiological Activity:\nMeasured in a cell proliferation/survival assay using IEC-18 rat small intestinal epithelial cell line. The ED50 for this effect is typically 0.3-1.2ug/ml\n\nEndotoxin: ~1EU/1ug (LAL)\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 3 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

W3038-10E

Size

10ug

Form

Supplied as a lyophilized powder in PBS, EDTA, CHAPS, BSA. Reconstitute with sterile PBS, 0.1% BSA to 0.1mg/ml.

Purity

~85% (SDS-PAGE)

References

1. Hardiman, G. et al. (1997) Cytogenet. Cell Genet. 77:278. 2. Katoh, M. (2008) Curr. Drug Targets 9:565. 3.Hausmann, G. et al. (2007) Nat. Rev. Mol. Cell Biol. 8:331. 4.Swiss Prot Accession # O00744. 5. Stevens, J.R. et al. (2010) J. Bone Miner. Res. 25:2138. 6. Bennett, C.N. et al. (2007) J. Bone Miner. Res. 22:1924. 7. Bennett, C.N. et al. (2005) Proc. Natl. Acad. Sci. USA 102:3324. 8. Wright, W.S. et al. (2007) Diabetes 56:295. 9.Abiola, M. et al. (2009) PLoS ONE 4:e8509. 10 .Ugur, S.A. and A. Tolun (2008) Hum. Mol. Genet. 17:2644. 11. Christodoulides, C. et al. (2006) Diabetologia 49:678. 12. Terauchi, M. et al. (2009) Cell Metab. 10:229. 13. Yoshikawa, H. et al. (2007) Mol. Biol. Cell 18:4292. 14. Holcombe, R.F. et al. (2002) J. Clin. Pathol: Mol. Pathol. 55:220.